Skip to main content
Premium Trial:

Request an Annual Quote

TIGR Dumps HP Servers for Sun Systems; Says HP Alphas 'Sluggish and Unreliable'

NEW YORK (GenomeWeb News) – The Institute for Genomic Research has replaced a cluster of Hewlett-Packard servers with technology made by Sun Microsystems, Sun said today.
 
TIGR will replace 15 HP Alpha servers in favor of three Sun Fire x64 servers to power its genomic assembler for molecular research, Sun said.
 
Sun said the new system will reduce energy consumption by “more than 70 percent” and can reduce purchasing and operating costs.
 
"Our aging HP Alpha servers were growing quite sluggish and unreliable, which caused delays in conducting research, and therefore, delivering our research results to the public,” Vadim Sapiro, director of IT at TIGR, said in a statement.
 
“The Alpha systems were also becoming cost prohibitive to operate: They required massive power and cooling systems and the lack of systems support continued to drive costs upward," he said.
 
Sapiro said TIGR “discovered” that three Sun Fire x64 servers powered by AMD Opteron processors running the 64-bit Linux OS “provided the same level of performance as our 15 HP Alpha servers.”
 
Beside the Sun Fire x64 servers, TIGR's genomic assembly software pipeline also uses Sun’s N1 Grid Engine.
 
Financial details were not disclosed.
 
An HP spokesperson said the company "is looking into" TIGR's statement.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more